The 750 mg NAD+ number has a recognizable research source: a 2019 human pilot examining changes in the metabolome during an intravenous infusion. It is a study amount, not a universally established wellness dose.
Its relevance depends on the route, observation period, and outcomes measured. A clinic citing the paper should explain those details rather than allowing “studied at 750 mg” to stand in for proof that its service improves energy, memory, or lifespan.
The 750 mg IV pilot describes metabolism during a specific infusion. It does not establish a general wellness dose, a home-injection schedule, or a longevity benefit.
Where the 750 mg figure comes from
Grant and colleagues studied NAD+ delivered intravenously over six hours and measured NAD-related compounds in plasma and urine. The original paper is useful for understanding what happened to the administered material during a controlled observation period.
The design does not establish a standard consumer treatment course. It also does not turn the total infusion amount into a home injection instruction.
The outcome was not a longevity result
Metabolite measurements can help investigate processing and clearance. They do not by themselves show that someone feels better, functions better, or lives longer. An article or advertisement should name the outcome that was actually measured before presenting it as a benefit.
Our evidence guide distinguishes biological plausibility, biomarker changes, and outcomes that matter in everyday life.
The six-hour setting is part of the evidence
A study’s administration period and clinical setting affect what can reasonably be inferred from it. The same total mass delivered through a different route or over a different period is not the same intervention. This guide does not reproduce an infusion-rate protocol or recommend that readers seek a particular rate.
Ask a clinic how its proposed service differs from the cited research and what evidence supports those differences.
Why the paper does not answer a home-vial question
A home subcutaneous prescription is absorbed through a different route and comes with its own formulation, concentration, and instructions. The IV paper cannot establish a matching syringe amount or a schedule for a multi-use vial. The injection versus IV comparison explains the practical distinction without assuming either route has proven anti-aging benefits.
How to assess a 750 mg clinic quote
Request the exact preparation, expected appointment duration, responsible clinician, included evaluation, and follow-up plan. Ask which claimed benefit is supported by a study of the proposed service. Compare written quotes within the same setting rather than equating a clinic session with the cost of an oral bottle.
FDA’s sterile-compounding notice remains relevant regardless of the amount printed on an infusion menu. A research citation does not verify an individual pharmacy or batch.
Sources & reading notes
Editorial source review updated September 19, 2026. Provider pages describe their own offers; inclusion does not verify a product or its results.
- Grant et al. (2019): NAD+ infusion metabolome pilot Small human IV study; metabolic observations do not prove longevity or everyday benefits.
- FDA: ingredients suitable for sterile compounding Safety notice describing reported reactions and ingredient-quality concerns.
- FDA: compounding questions and answers Explains that compounded drugs are not FDA-approved.
Educational information, not individualized medical advice. We do not claim medical review or firsthand treatment experience. Read our review standards and commercial disclosure.